REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (REGISTRY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01590589|
Recruitment Status : Completed
First Posted : May 3, 2012
Last Update Posted : September 15, 2017
This is a multi-centre, multi-national, prospective, observational study of Huntington's disease (HD) with a control group of volunteers to:
- obtain natural history data on many HD mutation carriers and individuals who are part of an HD family
- relate phenotypical characteristics (genetic modifiers / wet and dry biomarkers)
- expedite identification and recruitment of participants for clinical trials
- develop and validate sensitive and reliable outcome measures for detecting onset and change over the natural course of premanifest and manifest HD which may also be potential outcome measures for use in future clinical trials and clinical care
- plan for future research studies
|Condition or disease|
|Huntington Disease Huntington's Disease|
REGISTRY integrates prospectively and systematically collected clinical research data (e.g. phenotypical clinical features, family history, demographical characteristics) with access to biological specimens (e.g. blood, urine) obtained from individuals with manifest HD, unaffected individuals known to carry the HD mutation or at risk of carrying the HD mutation, and control research participants (e.g. spouses, siblings or offspring of HD mutation carriers known not to carry the HD mutation).
REGISTRY is an open-ended study and eligible subjects are assessed at annual study visits on the phenotypical characteristics of HD regardless of whether they display clinical symptoms and signs of the disease and of individuals who are part of an HD family (irrespective of their mutation carrier status). At each study visit, general clinical, motor function, behavior, cognitive, Health Economics, Quality of Life assessments are administered. In addition, participants are given the option to consent to the donation of biosamples for the purposes of mutation (CAG repeat length) testing and for research to identify biological modifiers and markers of HD. Biological specimens and phenotypical data are made available to qualified scientists whose projects are reviewed and approved by the Scientific and Bioethical Advisory Committee (SBAC) of EHDN. Successful applicants agree to accept the EHDN policies surrounding the use of the data/materials provided and publication of results (see data sharing and publication policies of EHDN, attached). Research projects should aim to advance scientific knowledge towards establishing clinically effective treatments that delay onset and/or slow the progression of the disease.
|Study Type :||Observational|
|Actual Enrollment :||10000 participants|
|Official Title:||REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN)|
|Study Start Date :||June 2004|
|Actual Primary Completion Date :||June 30, 2017|
|Actual Study Completion Date :||June 30, 2017|
- Phenotypical characteristics of HD [ Time Frame: 13 years ]The goal of the project is to collect longitudinal data on the phenotypical characteristics of HD gene mutation carriers.
Biospecimen Retention: Samples With DNA
- DNA from whole blood
- Lymphoblastoid cell lines
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01590589
Show 140 Study Locations
|Principal Investigator:||Bernhard Landwehrmeyer, Professor||University Hospital of Ulm / Dept. of Neurology|